The short version of obesity research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-08 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
A person with type 1 diabetes should balance insulin delivery to manage their blood glucose level. Occasionally, insufficient insulin can result in hyperglycemia. The appropriate response is to take a correction dose of insulin to reduce the blood sugar level and to consider adjusting the insulin regimen to deliver additional insulin in the future to prevent hyperglycemia. Conversely, excessive insulin delivery may result in hypoglycemia. The appropriate response is to treat the hypoglycemia and to consider adjusting the regimen to reduce insulin in the future. Somogyi and others have claimed that if prolonged hypoglycemia is untreated, then stress due to low blood sugar can result in a high blood glucose rebound. The physiological mechanisms driving the rebound are defensive. When the blood glucose level falls below normal, the body responds by releasing the endocrine hormone glucagon as well as the stress hormones epinephrine, cortisol and growth hormone. Glucagon facilitates release of glucose from the liver that raises the blood glucose immediately; the stress hormones cause insulin resistance for several hours, sustaining the elevated blood sugar.
== Artery == The tunica media is made up of smooth muscle cells, elastic tissue, and collagen. It lies between the tunica intima on the inside and the tunica externa on the outside. The middle coat (tunica media) is distinguished from the inner (tunica intima) by its color and by the transverse arrangement of its fibers.
Glucose is converted into glucose 6-phosphate by the action of glucokinase or hexokinase with conversion of ATP to ADP. Glucose-6-phosphate is converted into glucose-1-phosphate by the action of phosphoglucomutase, passing through the obligatory intermediate glucose-1,6-bisphosphate. Glucose-1-phosphate is converted into UDP-glucose by the action of the enzyme UDP-glucose pyrophosphorylase. Pyrophosphate is formed, which is later hydrolysed by pyrophosphatase into two phosphate molecules. The enzyme glycogenin is needed to create initial short glycogen chains, which are then lengthened and branched by the other enzymes of glycogenesis. Glycogenin, a homodimer, has a tyrosine residue on each subunit that serves as the anchor for the reducing end of glycogen. Initially, about seven UDP-glucose molecules are added to each tyrosine residue by glycogenin, forming α(1→4) bonds. Once a chain of seven glucose monomers is formed, glycogen synthase binds to the growing glycogen chain and adds UDP-glucose to the 4-hydroxyl group of the glucosyl residue on the non-reducing end of the glycogen chain, forming more α(1→4) bonds in the process. Branches are made by glycogen branching enzyme (also known as amylo-α(1:4)→α(1:6)transglycosylase), which transfers the end of the chain onto an earlier part via α-1:6 glycosidic bond, forming branches, which further grow by addition of more α-1:4 glycosidic units.
Vestiges of British ties were removed piecemeal by the government over the decade following UDI, and replaced with symbols and terminology intended to be more uniquely Rhodesian. A silver "Liberty Bell", based on the bell of the same name in Philadelphia, was cast during 1966 and rung by the Prime Minister 12 times each year on Independence Day (the anniversary of UDI), with some in the press erroneously believing the number of chimes signifying the number of years since the declaration of independence. The Union Jack and Rhodesia's Commonwealth-style national flag—a defaced Sky Blue Ensign with the Union Jack in the canton—continued to fly over government buildings, military bases and other official locations until 11 November 1968, the third anniversary of UDI, when they were superseded by a new national flag: a green-white-green vertical triband, charged centrally with the Rhodesian coat of arms. The Union Jack continued to be ceremonially raised at Cecil Square in Salisbury on 12 September each year as part of the Pioneers' Day holiday, which marked the anniversary of the establishment of Salisbury (and, by extension, Rhodesia) in 1890. Since Elizabeth II was still the Rhodesian head of state in the eyes of Smith's administration until 1970, "God Save the Queen" remained the Rhodesian national anthem, and continued to accompany official occasions such as the opening of the Rhodesian parliament.
Sources: en.wikipedia.org
== History == In 1943, diphenhydramine was discovered by chemist George Rieveschl and one of his students, Fred Huber, while they were conducting research into muscle relaxants at the University of Cincinnati. Huber first synthesized diphenhydramine. Rieveschl then worked with Parke-Davis to test the compound, and the company licensed the patent from him. In 1946, it became the first prescription antihistamine in the United States approved by the FDA. In the 1960s, diphenhydramine was found to weakly inhibit reuptake of the neurotransmitter serotonin. This discovery led to a search for viable antidepressants with similar structures and fewer side effects, culminating in the invention of fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI). A similar search had previously led to the synthesis of the first SSRI, zimelidine, from brompheniramine, also an antihistamine. In 1975, diphenhydramine was still available only by prescription in the US and required medical supervision.
== Consumption by region == Penis is a taboo food in many cultures, even those that consume copious offal; anthropologist Robert Rotenberg opines that the symbolic association of penis to coitus, urination and ejaculation makes consuming it off-putting. Even in areas where penis is consumed, it is typically a niche food and eaten under specific circumstances, such as when their purported health benefits are needed.
While the BPC was primarily political, Black Consciousness activists also established the Black Community Programmes (BCPs) to focus on improving healthcare and education and fostering black economic self-reliance. The BCPs had strong ecumenical links, being part-funded by a program on Christian action, established by the Christian Institute of Southern Africa and the South African Council of Churches. Additional funds came from the Anglo-American Corporation, the International University Exchange Fund, and Scandinavian churches. In 1972, the BCP hired Biko and Bokwe Mafuna, allowing Biko to continue his political and community work. In September 1972, Biko visited Kimberley, where he met the PAC founder and anti-apartheid activist Robert Sobukwe. Biko's banning order in 1973 prevented him from working officially for the BCPs from which he had previously earned a small stipend, but he helped to set up a new BPC branch in Ginsberg, which held its first meeting in the church of a sympathetic white clergyman, David Russell. Establishing a more permanent headquarters in Leopold Street, the branch served as a base from which to form new BCPs; these included self-help schemes such as classes in literacy, dressmaking and health education. For Biko, community development was part of the process of infusing black people with a sense of pride and dignity. Near King William's Town, a BCP Zanempilo Clinic was established to serve as a healthcare centre catering for rural black people who would not otherwise have access to hospital facilities.
=== Influenza === Flublok Quadrivalent is a licensed recombinant subunit vaccine for active immunisation against influenza. It contains HA proteins of four strains of influenza virus purified and extracted using the Baculovirus-insect expression system. The four viral strains are standardised annually according to United States Public Health Services (USPHS) requirements. Flublok Quadrivalent has a comparable safety profile to traditional trivalent and quadrivalent vaccine equivalents. Flublok is also associated with less local reactions (RR = 0.94, 95% CI 0.90–0.98, three RCTs, FEM, I2 = 0%, low‐ certainty evidence) and higher risk of chills (RR = 1.33, 95% CI 1.03–1.72, three RCTs, FEM, I2 = 14%, low‐certainty evidence).
== The Monolith Summer School == Since 2004, BIA Separations has organized and hosted the Monolith Summer School and Symposium (MSS) which takes place every 2 years. MSS was established as there were no dedicated conferences to this technology and to bring together the top international scientists and researchers in the area of monolith chromatography to share their experiences and innovative applications.
Sources: en.wikipedia.org
Michael Bailey, who found that homosexuality had a genetic possibility; Laura Allen and Roger Gorski of UCLA had conducted research on the anterior commissure; molecular geneticist Cassandra Smith; the editor of The Arizona Republic. Directed by Jeremy Taylor, produced by Oliver Morse, made by Windfall Films 18 October Antichaos, about order out of chaos, with Ian Stewart of the University of Warwick; Canadian mathematician Brian Goodwin of the Open University, and emergence; the American biologist Stuart Kauffman of the Santa Fe Institute, and Boolean networks; the Danish theoretical physicist Per Bak of Brookhaven National Laboratory; Christopher Langton of the Santa Fe Institute; the American ecologist Tom Ray of the University of Delaware; the economist W. Brian Arthur of Stanford University; J. Doyne Farmer of the Prediction Company; and the American physicist Thomas Valone (a writer on bioelectromagnetics) of the University of New Mexico. Narrated by Alun Lewis, directed by Yavar Abbas, produced by Geoff Deehan, made by Union Pictures 25 October The Strange Case of Crop Circles 2, showing what had changed from the previous documentary broadcast on 27 October 1991. Directed by Jill Freeman, produced by Michael Wills, made by Juniper Productions 1 November Zen on Wheels, about how Japanese car manufacturers moved a team to Newport Beach, California at the Toyota Calty Design Research, to find out what appealed to buyers of BMW and Mercedes cars, which resulted in the Lexus LS, which outsold Mercedes-Benz and BMW.
== Uses == Proline and its derivatives are often used as asymmetric catalysts in proline organocatalysis reactions. The CBS reduction and proline catalysed aldol condensation are prominent examples. In brewing, proteins rich in proline combine with polyphenols to produce haze (turbidity). L-Proline is an osmoprotectant and therefore is used in many pharmaceutical and biotechnological applications. The growth medium used in plant tissue culture may be supplemented with proline. This can increase growth, perhaps because it helps the plant tolerate the stresses of tissue culture. For proline's role in the stress response of plants, see § Biological activity.
== Veterinary use == Hydromorphone is used as an intravenous analgesic in cats and dogs. Hydromorphone's potency is 5–10 times greater than morphine when given intravenously and the length of effect is dose dependent with times ranging 1–8 hours. Anaesthetic recovery can be prolonged from long use of hydromorphone. Hydromorphone is not useful compared to morphine when given subcutaenously in cats or epidurally in cats and dogs. Hydromorphone can provide analgesia up to 12 hours when given intravenously in horses and is also effective when given intramuscular. Hydromorphone has minimal adverse effects in horses when compared to other opioids such as morphine.
In pharmacokinetics, a compartment is a defined volume of body fluids, typically of the human body, but also those of other animals with multiple organ systems. The meaning in this area of study is different from the concept of anatomic compartments, which are bounded by fasciae, the sheath of fibrous tissue that enclose mammalian organs. Instead, the concept focuses on broad types of fluidic systems. This analysis is used in attempts to mathematically describe distribution of small molecules throughout organisms with multiple compartments. Various multi-compartment models can be used in the areas of pharmacokinetics and pharmacology, in the support of efforts in drug discovery, and in environmental science. In humans and related organisms, there are five major body compartments: the blood plasma, interstitial fluids, fat tissues, intracellular fluids, and transcellular fluids, the latter of which includes fluids in the pleural (peritoneal) cavity. The relative percents of body mass of these are included in the pie chart above.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.